Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129648 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT01129648 is a Phase 2 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 87 participants.
The verdict
NCT01129648, a Phase 2 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
To evaluate safety and efficacy of BCX4208 alone and in combination with allopurinol in subjects with gout.
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG BCX4208
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01129648
The ClinicalTrials.gov registry entry for NCT01129648 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01129648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01129648 about?
NCT01129648 is a clinical study titled "Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout". To evaluate safety and efficacy of BCX4208 alone and in combination with allopurinol in subjects with gout.
What is the current status of trial NCT01129648?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2010-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01129648?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), BCX4208 (DRUG).
Who is sponsoring clinical trial NCT01129648?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.